Day 2 of EADV 2026 highlighted new findings involving GLP-1–associated nail changes, long-term atopic dermatitis control, emerging therapies, alopecia, and hidradenitis suppurativa. The second day of ...
Trispecific blockade of IL-4/IL-13 and upstream TSLP is intended to broaden type 2 inflammatory pathway coverage and potentially enhance durability versus single-axis inhibition. Week-16 EASI 75 rates ...
The National Eczema Association (NEA) has released the State of AD 2026 National Indicator Report, a Milliman analysis ...
ASC40-304 enrolled 240 completers from ASC40-303, administering denifanstat 50 mg QD for up to 40 additional weeks, with safety primary and efficacy assessed versus ASC40-303 baseline. IGA treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results